Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
Aliment Pharmacol Ther. 2024 May;59(10):1294-1295. doi: 10.1111/apt.17992.
NO ABSTRACT
PMID:38652769 | DOI:10.1111/apt.17992
![Google](https://www.google.com/images/branding/googlelogo/2x/googlelogo_light_color_92x30dp.png)
![Google Keep](https://www.gstatic.com/images/branding/product/1x/keep_48dp.png)
![Share on Linkedin](https://psychiatryai.com/wp-content/uploads/2023/10/linkedin-logo-png-2048-1.png)
Estimated reading time: 1 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Cool Evidence: Engaging Young People and Students in Real-World Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Real-Time Evidence Search [Psychiatry]
![](/wp-content/uploads/2024/04/pubmed.png)
AI Research
![](/wp-content/uploads/2024/05/Il5nR_nf_400x400-modified-1.png)
Editorial: Crystalising the burden of steatotic liver disease-Authors’ reply
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population Psychedelics in treatment of postraumatic stress disorder Review article: Hepatic steatosis and its associations with acute and chronic liver diseases Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies MDMA-assisted therapy for PTSD Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China Reply to: Frailty and ethics at the end of life: The importance of a comprehensive assessment New nomenclature for fatty liver disease Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics? The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD) A novel dual near-infrared fluorescent probe for bioimaging and visualization of viscosity in acute alcoholic liver injury Erythropoietin hyporesponsiveness in non-alcoholic fatty liver disease Spatial genomics: mapping human steatotic liver disease Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of… Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review Changes in the etiology of liver cirrhosis and the corresponding management strategies COVID-19 in Individuals with Chronic Liver Diseases Long-term risk of cardiovascular disease associated with MASLD and different cardiometabolic risk factors in IBD patients: A prospective cohort study Long-term risk of cardiovascular disease associated with MASLD and different cardiometabolic risk factors in IBD patients: A prospective cohort study Obituary: Travis Thompson-Editorial Association between the skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease: A cross-sectional study of NHANES 2017-2018 Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD) Home monitoring to detect progression of interstitial lung disease: A prospective cohort study A child with Kawasaki disease and acute pancreatitis: Atypical presentation Editorial: "What say you?" The promise and potential pitfalls of using automated and passive monitoring approaches to assess parenting behaviours from verbal and written communication Editorial: "What say you?" The promise and potential pitfalls of using automated and passive monitoring approaches to assess parenting behaviours from verbal and written communication Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective RETRACTION: Reduced self-harm on acute mental health wards following the implementation of a vision-based patient monitoring system: Evidence from five NHS trusts Editorial: Management of PJI/SSI after joint arthroplasty Editorial: Management of PJI/SSI after joint arthroplasty EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) Silibinin, a commonly used therapeutic agent for non-alcohol fatty liver disease, functions through upregulating intestinal expression of fibroblast growth factor 15/19 An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD) Gestational diabetes mellitus may predispose to metabolic dysfunction-associated steatotic liver disease Editorial on common mental health disorders and cognitive decline in a longitudinal Down syndrome cohort Crosstalk in extrahepatic and hepatic system in NAFLD/NASH Crosstalk in extrahepatic and hepatic system in NAFLD/NASH Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease Immune signature and therapeutic approach of natural killer cell in chronic liver disease and hepatocellular carcinoma Single nucleotide polymorphisms in the cannabinoid CB2 receptor: Molecular pharmacology and disease associations Editorial perspective: Transforming child and adolescent mental health services and systems (CAMHSS) around the globe - the importance of diversity, inclusion and equity in CAMHSS research An aggressive mediastinal EBV-associated large B cell lymphoma [Retracted] MicroRNA‑584 prohibits hepatocellular carcinoma cell proliferation and invasion by directly targeting BDNF Hedan tablet ameliorated non-alcoholic steatohepatitis by moderating NF-kappaB and lipid metabolism-related pathways via regulating hepatic metabolites The gut-liver axis in fatty liver disease: role played by natural products Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD When I say … active learning When I say … inclusive teaching Para-fluorofentanyl: Coincidence or intentional? Obituary: Kypros Kypri Response letter: Complexities in pericyte markers An update of contemporary insulin therapy Clinical features of individuals with laboratory values suggestive of advanced liver fibrosis when first treated for alcohol use disorder Collaborative research for psychosis prediction and prevention Ethical concerns related to the use of artificial intelligence in dermatopathology
Evidence Blueprint
Editorial: Crystalising the burden of steatotic liver disease-Authors’ reply
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
Editorial: Crystalising the burden of steatotic liver disease-Authors’ reply
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population Psychedelics in treatment of postraumatic stress disorder Review article: Hepatic steatosis and its associations with acute and chronic liver diseases The silent burden of non-alcoholic fatty liver disease in the elderly: A global burden of disease analysis Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies Review article: Current indications and selection criteria for early liver transplantation in severe alcohol-associated hepatitis Systematic review and meta-analysis: Association between liver fibrosis and subclinical atherosclerosis in nonalcoholic fatty liver disease Meta-analysis: Impact of intragastric balloon therapy on NAFLD-related parameters in patients with obesity Epidemiology and risk factors for histopathologic characteristics of non-alcoholic fatty liver disease in South America The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction-associated steatotic liver disease - The Gut and Obesity in Asia (GO-ASIA) Study Meta-analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non-alcoholic steatohepatitis and non-alcoholic steatohepatitis-related fibrosis MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease Systematic review: Glycomics as diagnostic markers for hepatocellular carcinoma Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis Improved health-related quality of life with semaglutide in people with non-alcoholic steatohepatitis: A randomised trial First in human randomised trial of J2H-1702: A novel 11β-hydroxysteroid dehydrogenase type 1 inhibitor for non-alcoholic steatohepatitis treatment MDMA-assisted therapy for PTSD Associations of dietary sugars with liver stiffness in Latino adolescents with obesity differ on PNPLA3 and liver disease severity Steatotic hepatocyte-derived extracellular vesicles promote β-cell apoptosis and diabetes via microRNA-126a-3p Potential Mechanisms Involving in the Pathogenesis of MASLD and Targets for Pharmacotherapy. Advancements in Metabolic Associated Steatotic Liver Disease (MASLD) Research: Diagnostics, Small Molecule Developments and Future Directions Commentary: The evidence base regarding the long-term effects of childhood mental disorder treatments needs to be strengthened - reply to Dekkers et al. (2023) Letter regarding 'Association of thyroid function with non-alcoholic fatty liver disease in recent-onset diabetes' Relationship of ferritin and hepcidin with disease severity in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus Reply to: Disease latency and new-user versus prevalent-user cohort designs: Implications for pharmacoepidemiology in dementia Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China The double roles of T cell-mediated immune response in the progression of MASLD Reply to: Comment on: Association of sulfonylureas with the risk of dementia: A population-based cohort study Reply to: Frailty and ethics at the end of life: The importance of a comprehensive assessment MBOAT7 in liver and extrahepatic diseases Liver disease mortality and hospitalisations among people with type 2 diabetes mellitus: A population-based study New nomenclature for fatty liver disease Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: A cross-sectional study Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease The significance of omega-3 fatty acids in the treatment of non-alcoholic fatty liver disease Reply to Ng: a closer look at late-onset psychoses for the general internist The promise of N-acetylcysteine in the treatment of obsessive-compulsive disorder From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus Therapeutic management of metabolic dysfunction associated steatotic liver disease Pharmacogenetic testing of CYP2D6, CYP2C19 and CYP2C9 in Denmark: Agreement between publicly funded genotyping tests and the subsequent phenotype classification Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics? Reply to: Positive aspects of caregiving attenuate the relationship between behavioral bother and anxiety and depressive symptoms in dementia family caregivers. Geriatr. Gerontol. Int. 2023;1. https://doi.org/10.1111/ggi.1460 Exclusive liquor and cocktail consumption is associated with at-risk fibrosis among nonheavy alcohol users with metabolic dysfunction-associated steatotic liver disease Association of liver fibrosis with extrahepatic cancer in steatotic liver disease patients with PNPLA3 I148M GG genotype The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD) A novel dual near-infrared fluorescent probe for bioimaging and visualization of viscosity in acute alcoholic liver injury Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study Erythropoietin hyporesponsiveness in non-alcoholic fatty liver disease Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome Editorial: Prevention is the best cure - or is it? A cautionary tale Non-alcoholic fatty liver disease, women's health and the role of the environment Spatial genomics: mapping human steatotic liver disease Prevalence, distribution and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of… Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice Plastic compounds and liver diseases: Whether bisphenol A is the only culprit